A guide to leveraging EU JCA dossiers to optimize national market access
JCAs are reshaping the HTA landscape across Europe, and health technology developers are learning how to work with the new process.
In this white paper, experts from OPEN Health explore the opportunities afforded by the JCA dossier to incorporate evidence, and context to support future national HTA and reimbursement discussions.
Featuring practical guidance for dossier development, the paper highlights opportunities to strengthen the interpretation of patient outcomes, treatment patterns, and real-world evidence, while remaining within the scope of the JCA.
We have reserved a copy of this white paper for you.
We are excited to share our latest thinking with you.
Please fill out the form to download the whitepaper.
OPEN Health authors:
At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact.
By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.
